BASi Names Philip A. Downing Senior Vice President of Preclinical Services
March 08 2017 - 2:12PM
Business Wire
Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the
“Company”) today announced that Philip A. Downing has been
promoted to Senior Vice President, Preclinical Services.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170308006221/en/
Philip A. Downing, Senior Vice President
of Preclinical Services (Photo: Business Wire)
“Philip has demonstrated the ability to cultivate a strong,
capable team fostered by a customer-first culture that is driving
continued success in top line growth, quality standards and on time
delivery. A trusted partner in client relationships, Philip's
extensive experience is matched by his judgment, technical
capabilities and management skills. Philip’s leadership and
guidance during this time of transition for BASi has also been
instrumental to the Board and me. His leadership and vision will
continue to be an asset to BASi and further support our client’s
drug discovery efforts,” said Larry Boulet, BASI Chairman of the
Board. Mr. Downing continues to serve BASi as the acting Principal
Executive Officer.
Philip has over 24 years of pharmaceutical experience in drug
discovery, toxicology, non clinical and clinical research. After
receiving a B.A. in Chemistry and Biology from Indiana University
in 1993, Mr. Downing worked for a clinical research laboratory, GFi
Pharmaceuticals (now Covance Labs), as an Analytical Scientist
designing and validating radiolabeled and non-radiolabeled assays
used to support clinical ADME studies. Philip has worked at BASi
for nearly 20 years, starting as an Analytical Chemist and rapidly
moving into influential leadership positions throughout his
tenure.
This appointment continues to position BASi as the partner of
choice for early-stage drug development, to enhance the Company’s
ability to meet the needs of its clients and to drive future
growth.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract
research services and monitoring instruments to the world's leading
drug development companies and medical research organizations. The
company focuses on developing innovative services and products that
increase efficiency and reduce the cost of taking a new drug to
market. Visit www.BASinc.com for more information about BASi.
This release may contain forward-looking statements that are
subject to risks and uncertainties including, but not limited to,
risks and uncertainties related to changes in the market and demand
for our products and services, the development, marketing and sales
of products and services, changes in technology, industry standards
and regulatory standards, and various market and operating risks
detailed in the company's filings with the Securities and Exchange
Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170308006221/en/
Bioanalytical Systems, Inc.Jill Blumhoff,
765-497-8381Chief Financial Officer & Vice President of
Financejblumhoff@BASinc.com
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Sep 2023 to Sep 2024